Index -
P/E -
EPS (ttm) -
Insider Own 53.70%
Shs Outstand 31.85M
Perf Week -4.44%
Market Cap 719.81M
Forward P/E -
EPS next Y -
Insider Trans 98.80%
Shs Float 14.75M
Perf Month -
Income -
PEG -
EPS next Q -
Inst Own -
Short Float -
Perf Quarter -
Sales -
P/S -
EPS this Y -
Inst Trans -
Short Ratio -
Perf Half Y -
Book/sh -3.07
P/B -
EPS next Y -
ROA -
Short Interest -
Perf Year -
Cash/sh 1.74
P/C 13.03
EPS next 5Y -
ROE -
52W Range 20.29 - 26.08
Perf YTD -4.44%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -
52W High -13.34%
Beta -
Dividend TTM -
Quick Ratio 7.17
Sales past 5Y 0.00%
Gross Margin -
52W Low 11.41%
ATR (14) 2.78
Dividend Ex-Date -
Current Ratio 7.17
EPS Y/Y TTM -
Oper. Margin -
RSI (14) -
Volatility - -
Employees -
Debt/Eq 0.01
Sales Y/Y TTM -
Profit Margin -
Recom -
Target Price -
Option/Short No / Yes
LT Debt/Eq 0.00
EPS Q/Q -
Payout -
Rel Volume 0.81
Prev Close 21.23
Sales Surprise -
EPS Surprise -
Sales Q/Q -
Earnings -
Avg Volume 469.70K
Price 22.60
SMA20 3.64%
SMA50 3.64%
SMA200 3.64%
Trades
Volume 328,560
Change 6.45%
Sep-18-24 03:19AM
Sep-16-24 04:05PM
Sep-12-24 07:11PM
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. Its product candidates and programs include MBX 2109, MBX 1416, and obesity portfolio. The company was founded by Peter Kent Hawryluk and Richard D. DiMarchi in August 2018 and is headquartered in Carmel, IN.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Mathers Edward T Director Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:28 PM BASKETT FOREST 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:26 PM Behbahani Ali 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:24 PM Chang Carmen 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:23 PM Florence Anthony A. Jr. 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:21 PM Makhzoumi Mohamad 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:20 PM Walker Paul Edward 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:18 PM Yang Rick 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:17 PM SANDELL SCOTT D 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:14 PM ORBIMED ADVISORS LLC Director Sep 16 '24 Buy 16.00 750,000 12,000,000 3,158,428 Sep 17 08:13 PM New Enterprise Associates 17, 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:12 PM Frazier Life Sciences X, L.P. 10% Owner Sep 16 '24 Buy 16.00 625,000 10,000,000 4,552,774 Sep 17 08:11 PM Heron Patrick J Director Sep 16 '24 Buy 16.00 625,000 10,000,000 4,552,774 Sep 17 08:09 PM Aynechi Tiba Director Sep 16 '24 Buy 16.00 750,000 12,000,000 2,136,335 Sep 17 08:05 PM GORDON CARL L Director Sep 16 '24 Buy 16.00 750,000 12,000,000 3,158,428 Sep 17 08:05 PM
Index RUT
P/E -
EPS (ttm) -25.49
Insider Own 36.37%
Shs Outstand 8.02M
Perf Week -13.59%
Market Cap 332.94M
Forward P/E -
EPS next Y -9.79
Insider Trans 5.57%
Shs Float 5.92M
Perf Month -22.21%
Income -92.22M
PEG -
EPS next Q -2.55
Inst Own 62.88%
Short Float 4.86%
Perf Quarter 1.19%
Sales 0.00M
P/S -
EPS this Y 82.24%
Inst Trans -28.19%
Short Ratio 3.31
Perf Half Y -44.92%
Book/sh 21.34
P/B 1.68
EPS next Y -3.86%
ROA -56.06%
Short Interest 0.29M
Perf Year 262.53%
Cash/sh 17.12
P/C 2.09
EPS next 5Y -
ROE -75.75%
52W Range 4.57 - 97.91
Perf YTD -25.31%
Dividend Est. -
P/FCF -
EPS past 5Y -11.67%
ROI -39.06%
52W High -63.44%
Beta 3.85
Dividend TTM -
Quick Ratio 13.28
Sales past 5Y -26.84%
Gross Margin -
52W Low 682.51%
ATR (14) 4.27
Dividend Ex-Date -
Current Ratio 13.28
EPS Y/Y TTM 73.20%
Oper. Margin 0.00%
RSI (14) 37.84
Volatility 9.81% 10.12%
Employees 101
Debt/Eq 0.19
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 123.75
Option/Short No / Yes
LT Debt/Eq 0.19
EPS Q/Q 83.89%
Payout -
Rel Volume 0.87
Prev Close 38.50
Sales Surprise -
EPS Surprise -0.06%
Sales Q/Q -
Earnings Aug 13 AMC
Avg Volume 86.90K
Price 35.80
SMA20 -16.74%
SMA50 -18.07%
SMA200 -30.12%
Trades
Volume 65,424
Change -7.01%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-14-24 Initiated
William Blair
Outperform
$180
Mar-28-24 Reiterated
H.C. Wainwright
Buy
$100 → $115
Feb-27-24 Initiated
BMO Capital Markets
Outperform
$120
Dec-04-23 Initiated
H.C. Wainwright
Buy
$100
Nov-29-23 Initiated
RBC Capital Mkts
Outperform
$70
Nov-10-23 Initiated
Piper Sandler
Overweight
$180
Feb-15-23 Downgrade
Chardan Capital Markets
Buy → Neutral
Feb-13-23 Downgrade
Cowen
Outperform → Market Perform
Sep-22-21 Downgrade
Goldman
Buy → Neutral
$12 → $9
Jan-27-21 Upgrade
JP Morgan
Neutral → Overweight
$56
Dec-22-20 Initiated
B. Riley Securities
Buy
$79
Jul-14-20 Initiated
Oppenheimer
Outperform
$36
May-18-20 Downgrade
JP Morgan
Overweight → Neutral
$27
Oct-28-19 Initiated
JP Morgan
Overweight
$25
Oct-28-19 Initiated
Goldman
Buy
$30
Oct-28-19 Initiated
Cowen
Outperform
Show Previous Ratings
Sep-16-24 08:00AM
Sep-10-24 08:00AM
Aug-28-24 08:00AM
Aug-27-24 08:00AM
Aug-13-24 04:01PM
08:00AM
Loading…
Jul-01-24 08:00AM
Jun-25-24 12:53PM
May-30-24 04:01PM
May-20-24 02:30PM
May-14-24 10:55PM
04:01PM
Apr-18-24 08:30AM
Apr-01-24 04:01PM
Mar-26-24 04:01PM
Feb-27-24 09:55AM
08:00AM
Loading…
08:00AM
Feb-09-24 09:55AM
Jan-18-24 08:00AM
Jan-04-24 08:00AM
Dec-07-23 08:00AM
Nov-28-23 08:00AM
Nov-03-23 03:31PM
12:19PM
Aug-10-23 04:01PM
Jul-17-23 11:59AM
Jul-14-23 11:22AM
06:30AM
May-12-23 04:01PM
Mar-10-23 07:30AM
Feb-27-23 07:30AM
01:55PM
Loading…
Feb-13-23 01:55PM
(American City Business Journals) -80.54%
11:17AM
08:05AM
Dec-19-22 07:30AM
Dec-15-22 07:30AM
Nov-17-22 07:30AM
Nov-08-22 04:05PM
Oct-12-22 07:30AM
Aug-30-22 07:30AM
Aug-09-22 04:05PM
(Business Wire) -11.11%
+9.00%
Jun-24-22 09:03AM
May-25-22 12:00PM
May-18-22 07:30AM
May-04-22 04:30PM
Apr-22-22 07:30AM
Apr-08-22 05:00PM
Mar-15-22 07:30AM
Mar-10-22 06:35PM
Feb-28-22 07:30AM
Jan-14-22 05:43AM
Jan-04-22 07:30AM
Dec-28-21 02:38AM
Dec-09-21 01:18PM
07:30AM
Nov-30-21 05:53AM
Nov-15-21 12:25PM
07:30AM
Nov-09-21 07:30AM
Nov-08-21 03:00PM
Oct-27-21 07:30AM
Oct-21-21 07:30AM
Oct-01-21 08:23AM
Sep-22-21 11:18AM
07:30AM
Sep-08-21 07:30AM
Aug-30-21 05:10PM
Aug-12-21 04:06PM
08:45AM
07:30AM
Aug-04-21 03:00PM
Aug-02-21 03:05PM
02:30PM
12:30PM
12:30PM
11:00AM
10:00AM
09:16AM
09:09AM
05:50AM
03:27AM
Aug-01-21 10:38AM
06:36AM
Jul-30-21 08:49PM
07:19PM
07:10PM
05:15PM
02:57PM
01:30PM
12:40PM
11:30AM
11:30AM
11:00AM
10:00AM
10:00AM
09:30AM
09:00AM
05:18AM
Jul-29-21 08:47PM
05:29PM
04:02PM
Korro Bio, Inc. is an RNA editing company, which engages in the discovery and development of genetic medicines. The company was founded by Nessan Bermingham, Jean-Francois Formela, Joshua Rosenthal, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Colletti Steve Former Officer Aug 30 '24 Proposed Sale 49.24 10,303 507,326 Aug 30 05:28 PM New Enterprise Associates 17, 10% Owner Apr 22 '24 Buy 56.00 17,857 999,992 1,090,793 Apr 24 05:00 PM BASKETT FOREST 10% Owner Apr 22 '24 Buy 56.00 17,857 999,992 1,090,793 Apr 24 05:00 PM Florence Anthony A. Jr. 10% Owner Apr 22 '24 Buy 56.00 17,857 999,992 1,090,793 Apr 24 05:00 PM Walker Paul Edward 10% Owner Apr 22 '24 Buy 56.00 17,857 999,992 1,090,793 Apr 24 05:00 PM Chang Carmen 10% Owner Apr 22 '24 Buy 56.00 17,857 999,992 1,090,793 Apr 24 05:00 PM Mathers Edward T 10% Owner Apr 22 '24 Buy 56.00 17,857 999,992 1,090,793 Apr 24 05:00 PM Yang Rick 10% Owner Apr 22 '24 Buy 56.00 17,857 999,992 1,090,793 Apr 24 05:00 PM Makhzoumi Mohamad 10% Owner Apr 22 '24 Buy 56.00 17,857 999,992 1,090,793 Apr 24 05:00 PM SANDELL SCOTT D 10% Owner Apr 22 '24 Buy 56.00 17,857 999,992 1,090,793 Apr 24 05:00 PM Atlas Venture Opportunity Fund 10% Owner Apr 22 '24 Buy 56.00 17,857 999,992 195,074 Apr 23 05:23 PM Lucchino David L. Director Nov 22 '23 Sale 37.69 1,156 43,573 22,150 Nov 27 08:48 PM Lucchino David L. Director Nov 10 '23 Sale 41.97 968 40,632 23,306 Nov 22 04:05 PM
Index RUT
P/E -
EPS (ttm) -0.42
Insider Own 44.31%
Shs Outstand 138.14M
Perf Week 9.54%
Market Cap 757.26M
Forward P/E -
EPS next Y -0.43
Insider Trans 0.00%
Shs Float 91.67M
Perf Month 2.69%
Income -75.29M
PEG -
EPS next Q -0.11
Inst Own 51.05%
Short Float 10.27%
Perf Quarter 18.57%
Sales 0.00M
P/S -
EPS this Y -35.06%
Inst Trans 2.44%
Short Ratio 5.34
Perf Half Y -5.92%
Book/sh 0.74
P/B 6.25
EPS next Y 3.85%
ROA -58.02%
Short Interest 9.41M
Perf Year 22.03%
Cash/sh 0.74
P/C 6.23
EPS next 5Y -
ROE -79.48%
52W Range 3.12 - 5.70
Perf YTD -2.11%
Dividend Est. -
P/FCF -
EPS past 5Y 29.09%
ROI -58.72%
52W High -19.29%
Beta 0.96
Dividend TTM -
Quick Ratio 11.29
Sales past 5Y -20.00%
Gross Margin -
52W Low 47.69%
ATR (14) 0.22
Dividend Ex-Date -
Current Ratio 11.29
EPS Y/Y TTM -51.68%
Oper. Margin 0.00%
RSI (14) 58.58
Volatility 5.14% 4.97%
Employees 37
Debt/Eq 0.26
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 10.79
Option/Short Yes / Yes
LT Debt/Eq 0.26
EPS Q/Q -62.62%
Payout -
Rel Volume 0.58
Prev Close 4.64
Sales Surprise -
EPS Surprise -15.05%
Sales Q/Q -
Earnings Aug 12 AMC
Avg Volume 1.76M
Price 4.60
SMA20 5.81%
SMA50 4.40%
SMA200 0.96%
Trades
Volume 888,479
Change -0.85%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-15-24 Initiated
JMP Securities
Mkt Outperform
$8
Nov-07-23 Initiated
Guggenheim
Buy
$7
May-16-23 Upgrade
Jefferies
Hold → Buy
$2 → $4
Mar-31-23 Downgrade
Jefferies
Buy → Hold
$2
Mar-16-21 Initiated
Piper Sandler
Overweight
$7
Mar-15-21 Initiated
Oppenheimer
Outperform
$4
Jun-13-19 Reiterated
H.C. Wainwright
Buy
$22 → $6
Jun-13-19 Downgrade
Ladenburg Thalmann
Buy → Neutral
$21 → $3
Jun-13-19 Downgrade
JMP Securities
Mkt Outperform → Mkt Perform
Aug-13-18 Resumed
ROTH Capital
Neutral
$12
Jan-03-18 Initiated
Ladenburg Thalmann
Buy
$35
Sep-27-17 Resumed
ROTH Capital
Buy
$40
Sep-22-17 Initiated
Jefferies
Buy
$20
Sep-11-17 Initiated
JMP Securities
Mkt Outperform
$20
Show Previous Ratings
Sep-08-24 06:45AM
Sep-06-24 04:05PM
Sep-03-24 04:05PM
Sep-01-24 10:26PM
Aug-29-24 08:41PM
04:05PM
Loading…
Aug-16-24 04:05PM
Aug-15-24 08:05AM
Aug-12-24 04:05PM
Jun-29-24 08:35PM
06:30PM
Jun-28-24 08:50AM
Jun-26-24 07:41AM
06:30AM
Jun-25-24 08:05PM
Jun-19-24 09:00AM
06:00AM
Loading…
Jun-11-24 06:00AM
May-29-24 08:05AM
May-21-24 08:20AM
May-19-24 12:15PM
May-16-24 04:05PM
May-09-24 10:55PM
04:05PM
May-07-24 04:05PM
(Business Wire) +6.26%
-5.13%
Apr-08-24 08:05AM
Mar-22-24 04:05PM
Mar-07-24 10:54PM
04:05PM
Mar-06-24 04:05PM
Feb-02-24 08:05AM
Jan-31-24 08:05AM
03:01PM
Loading…
Dec-30-23 03:01PM
Dec-21-23 08:05AM
Dec-20-23 08:05AM
Dec-15-23 04:05PM
Nov-21-23 08:05AM
Nov-09-23 04:05PM
Nov-08-23 04:05PM
Oct-06-23 04:05PM
Sep-27-23 07:29PM
Sep-17-23 10:54AM
Sep-12-23 09:12AM
Sep-05-23 04:05PM
Aug-10-23 04:05PM
Aug-04-23 04:05PM
Jul-13-23 07:00AM
Jun-26-23 04:05PM
08:05AM
Jun-02-23 08:05AM
May-28-23 08:26AM
May-16-23 12:32PM
May-15-23 08:05AM
May-05-23 04:05PM
Apr-03-23 07:33AM
Mar-31-23 04:05PM
Mar-30-23 04:05PM
Mar-20-23 06:35AM
Mar-17-23 06:47AM
Mar-16-23 06:51AM
Mar-15-23 06:44AM
Mar-13-23 06:32AM
Mar-10-23 07:04AM
Mar-09-23 06:33AM
Mar-08-23 06:30AM
Mar-07-23 06:34AM
Mar-06-23 04:05PM
07:22AM
Mar-03-23 06:38AM
Mar-02-23 06:44AM
Mar-01-23 06:01AM
Feb-28-23 04:05PM
06:43AM
Feb-27-23 06:50AM
Feb-23-23 07:21AM
Feb-22-23 06:56AM
Feb-21-23 07:35AM
Feb-17-23 06:27AM
Feb-16-23 07:28AM
Feb-15-23 07:01AM
06:24AM
Feb-14-23 08:05AM
06:23AM
Feb-13-23 07:30AM
Feb-10-23 06:42AM
Feb-09-23 06:51AM
Feb-08-23 06:45AM
Feb-07-23 06:46AM
Feb-06-23 06:56AM
Feb-03-23 06:32AM
Feb-02-23 06:43AM
Feb-01-23 06:14AM
Jan-31-23 06:50AM
Jan-30-23 06:42AM
Jan-27-23 03:47PM
07:00AM
Jan-26-23 06:44AM
Jan-25-23 06:39AM
Jan-24-23 06:48AM
Jan-23-23 06:58AM
Jan-20-23 08:05AM
06:55AM
Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Pauls Matthew CHIEF EXECUTIVE OFFICER Dec 28 '23 Sale 4.71 84,000 395,900 1,302,674 Dec 29 04:35 PM Lowrance David L CHIEF FINANCIAL OFFICER Dec 28 '23 Sale 4.71 10,000 47,131 342,355 Dec 29 04:34 PM Elam Nevan C Director Dec 28 '23 Option Exercise 1.30 53,758 69,722 116,343 Dec 29 04:33 PM Elam Nevan C Director Dec 28 '23 Sale 4.71 93,843 442,291 22,500 Dec 29 04:33 PM Hawkins Richard J Director Dec 11 '23 Option Exercise 0.82 10,841 8,890 12,741 Dec 12 06:09 PM Elam Nevan C Director Dec 11 '23 Option Exercise 0.82 10,841 8,890 40,085 Dec 12 06:08 PM
Index -
P/E -
EPS (ttm) -2.35
Insider Own 14.33%
Shs Outstand 87.75M
Perf Week -9.39%
Market Cap 48.67M
Forward P/E -
EPS next Y -0.66
Insider Trans -0.68%
Shs Float 76.12M
Perf Month -26.71%
Income -206.00M
PEG -
EPS next Q -0.25
Inst Own 74.25%
Short Float 2.55%
Perf Quarter -50.65%
Sales 0.00M
P/S -
EPS this Y 28.07%
Inst Trans 63.56%
Short Ratio 3.51
Perf Half Y -57.53%
Book/sh 0.95
P/B 0.58
EPS next Y 56.98%
ROA -86.62%
Short Interest 1.94M
Perf Year -74.52%
Cash/sh 1.39
P/C 0.40
EPS next 5Y 26.70%
ROE -121.54%
52W Range 0.54 - 3.40
Perf YTD -79.93%
Dividend Est. -
P/FCF -
EPS past 5Y 0.51%
ROI -170.84%
52W High -83.91%
Beta 1.15
Dividend TTM -
Quick Ratio 3.57
Sales past 5Y 0.00%
Gross Margin -
52W Low 1.44%
ATR (14) 0.06
Dividend Ex-Date -
Current Ratio 3.57
EPS Y/Y TTM -21.39%
Oper. Margin 0.00%
RSI (14) 36.69
Volatility 9.30% 10.62%
Employees 131
Debt/Eq 0.47
Sales Y/Y TTM -
Profit Margin -
Recom 2.71
Target Price 2.77
Option/Short Yes / Yes
LT Debt/Eq 0.44
EPS Q/Q 25.76%
Payout -
Rel Volume 0.90
Prev Close 0.58
Sales Surprise -
EPS Surprise 9.77%
Sales Q/Q -
Earnings Aug 07 AMC
Avg Volume 553.93K
Price 0.55
SMA20 -15.65%
SMA50 -25.19%
SMA200 -58.88%
Trades
Volume 432,381
Change -4.95%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-17-24 Downgrade
Jefferies
Buy → Hold
$6 → $1.50
Jan-16-24 Downgrade
Cantor Fitzgerald
Overweight → Neutral
Dec-18-23 Upgrade
William Blair
Mkt Perform → Outperform
Dec-08-23 Resumed
Jefferies
Buy
$9 → $6
Sep-27-23 Initiated
JMP Securities
Mkt Outperform
$11
May-12-23 Upgrade
Jefferies
Hold → Buy
$6 → $9
Mar-07-23 Initiated
Piper Sandler
Overweight
$22
Sep-12-22 Downgrade
SMBC Nikko
Neutral → Underperform
$2
Dec-22-21 Downgrade
William Blair
Outperform → Mkt Perform
Dec-22-21 Downgrade
SVB Leerink
Outperform → Mkt Perform
$17
Dec-22-21 Downgrade
Jefferies
Buy → Hold
Dec-22-21 Downgrade
Cowen
Outperform → Market Perform
Dec-22-21 Downgrade
BofA Securities
Buy → Underperform
$155 → $12
Aug-26-21 Initiated
Morgan Stanley
Equal-Weight
$88
Jul-15-21 Initiated
Cowen
Outperform
May-18-21 Initiated
H.C. Wainwright
Buy
$230
Feb-24-21 Initiated
Cantor Fitzgerald
Overweight
$218
Jan-15-21 Initiated
BofA Securities
Buy
$145
Dec-21-20 Initiated
SVB Leerink
Outperform
$150
Feb-27-20 Initiated
Barclays
Underweight
$36
Show Previous Ratings
Aug-07-24 11:54PM
04:02PM
Jun-25-24 04:02PM
May-28-24 07:02AM
May-10-24 04:02PM
10:56PM
Loading…
May-09-24 10:56PM
04:02PM
May-03-24 07:31AM
Apr-09-24 06:31AM
Apr-04-24 08:36AM
Mar-16-24 05:31AM
Mar-14-24 09:54PM
04:02PM
Feb-26-24 07:02AM
Feb-12-24 07:02AM
09:35AM
Loading…
Jan-18-24 09:35AM
Jan-17-24 12:10PM
Jan-16-24 11:36AM
09:40AM
09:28AM
07:27AM
07:17AM
07:02AM
07:00AM
05:09AM
Nov-13-23 05:01PM
04:02PM
Sep-27-23 12:10PM
Aug-30-23 04:05PM
Aug-09-23 04:02PM
(GlobeNewswire) -9.09%
-7.96%
04:05PM
Loading…
Aug-02-23 04:05PM
08:20AM
Jun-12-23 07:02AM
Jun-05-23 07:02AM
May-13-23 08:05AM
May-12-23 05:00PM
(Motley Fool) +8.89%
+9.93%
May-09-23 04:02PM
Mar-07-23 04:05PM
(Motley Fool) +21.30%
-6.72%
Mar-06-23 04:02PM
Jan-26-23 05:33AM
Dec-15-22 11:35AM
Dec-09-22 12:00PM
Nov-29-22 07:02AM
Nov-10-22 09:02AM
Nov-07-22 04:05PM
Oct-14-22 06:35PM
Sep-30-22 11:48AM
Sep-24-22 08:32AM
Sep-19-22 07:00AM
Sep-12-22 07:02AM
Sep-09-22 08:47AM
07:00AM
Aug-31-22 02:10PM
Aug-04-22 04:04PM
Jul-25-22 04:05PM
Jul-08-22 10:18AM
May-06-22 04:05PM
Apr-28-22 06:00PM
Apr-19-22 06:15PM
Apr-12-22 06:15PM
Apr-09-22 10:03AM
Mar-28-22 06:15PM
Mar-22-22 06:15PM
Mar-15-22 06:00PM
Mar-07-22 10:39AM
Mar-03-22 11:05AM
(American City Business Journals)
Mar-01-22 04:05PM
Feb-25-22 06:00PM
Feb-21-22 09:53AM
Feb-17-22 02:38AM
Feb-08-22 01:38PM
Feb-07-22 01:38PM
Feb-04-22 06:00PM
Feb-01-22 01:38PM
08:00AM
Jan-24-22 06:15PM
01:53PM
Jan-12-22 12:09PM
Jan-09-22 06:26AM
Jan-06-22 08:17AM
Jan-05-22 06:59AM
Jan-04-22 10:00AM
09:40AM
Dec-22-21 04:37PM
(American City Business Journals) -89.87%
+22.22%
12:36PM
10:41AM
09:07AM
Dec-21-21 07:15PM
Dec-20-21 08:32AM
Dec-08-21 07:38PM
07:38PM
Nov-30-21 07:00AM
Nov-19-21 10:27AM
(American City Business Journals)
08:40AM
Nov-08-21 04:05PM
Oct-25-21 08:00AM
Oct-24-21 03:35PM
Sep-30-21 11:12AM
08:39AM
Sep-29-21 08:47AM
Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in San Carlos, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Alexander Robert Officer Sep 11 '24 Proposed Sale 0.58 37,311 21,805 Sep 11 03:51 PM Lee Chin Hyok Officer Sep 09 '24 Proposed Sale 0.65 45,320 29,336 Sep 09 04:29 PM Radford Harlan Baird Officer Sep 06 '24 Proposed Sale 0.64 13,665 8,808 Sep 06 03:53 PM Tomasi Adam Officer Sep 06 '24 Proposed Sale 0.64 21,961 14,156 Sep 06 03:46 PM Radford Harlan Baird Chief Financial Officer Jun 28 '24 Sale 1.01 87,064 87,935 204,390 Jul 02 05:00 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite